ストックスクリーナーアプリを入手
29.69
2.34%
0.68
前日終値:
$29.01
開ける：
$29.13
24時間の取引高:
1.35M
Relative Volume:
0.75
時価総額：
$2.86B
収益：
$522.75M
当期純損益:
$-558.99M
株価収益率:
-4.5889
EPS:
-6.47
ネットキャッシュフロー:
$-439.53M
1週間 パフォーマンス:
+7.81%
1か月 パフォーマンス:
+9.15%
6か月 パフォーマンス:
-30.12%
1年 パフォーマンス:
-42.61%
1日の値動き範囲:
$29.07
$30.10
1週間の範囲:
$27.00
$30.10
52週間の値動き範囲:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
名前
Ultragenyx Pharmaceutical Inc
セクター
電話
415-483-8800
住所
60 LEVERONI COURT, NOVATO, CA
RARE を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
29.69 | 2.80B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.79 | 100.07B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
580.41 | 59.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.91 | 58.03B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
653.83 | 39.93B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
321.36 | 36.82B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-28 | 再開されました | H.C. Wainwright | Buy |
| 2025-05-28 | 開始されました | William Blair | Outperform |
| 2024-06-06 | アップグレード | Goldman | Neutral → Buy |
| 2024-04-22 | 開始されました | RBC Capital Mkts | Outperform |
| 2023-12-08 | 開始されました | Wells Fargo | Overweight |
| 2023-06-14 | 再開されました | Credit Suisse | Outperform |
| 2023-06-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-04-26 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-01-18 | 再開されました | Canaccord Genuity | Buy |
| 2022-12-30 | 再開されました | H.C. Wainwright | Buy |
| 2022-11-03 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-08-01 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-03-16 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-09-30 | 開始されました | H.C. Wainwright | Buy |
| 2021-08-19 | 開始されました | UBS | Sell |
| 2021-07-15 | 開始されました | Guggenheim | Neutral |
| 2021-06-29 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Neutral |
| 2021-05-06 | アップグレード | Citigroup | Neutral → Buy |
| 2021-05-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2021-04-26 | 再開されました | Credit Suisse | Neutral |
| 2021-03-02 | 再開されました | Stifel | Buy |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-07 | ダウングレード | Wedbush | Outperform → Neutral |
| 2020-11-24 | 再開されました | Evercore ISI | In-line |
| 2020-11-12 | ダウングレード | BofA Securities | Buy → Neutral |
| 2019-08-02 | 再開されました | Wedbush | Outperform |
| 2019-03-27 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | 再開されました | Raymond James | Outperform |
| 2019-01-02 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | アップグレード | Citigroup | Sell → Neutral |
| 2018-09-10 | 開始されました | Morgan Stanley | Equal-Weight |
| 2018-06-21 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | アップグレード | Barclays | Equal Weight → Overweight |
| 2018-05-10 | 開始されました | Goldman | Neutral |
| 2018-04-18 | アップグレード | SunTrust | Hold → Buy |
| 2018-03-22 | 再開されました | Piper Jaffray | Overweight |
| 2018-02-21 | 繰り返されました | Stifel | Buy |
| 2018-01-22 | アップグレード | Evercore ISI | In-line → Outperform |
| 2018-01-18 | 開始されました | Credit Suisse | Outperform |
| 2017-12-05 | 繰り返されました | Barclays | Equal Weight |
| 2017-12-04 | アップグレード | Jefferies | Hold → Buy |
| 2017-09-14 | アップグレード | Wedbush | Neutral → Outperform |
すべてを表示
Ultragenyx Pharmaceutical Inc (RARE) 最新ニュース
What are analysts’ price targets for Ultragenyx Pharmaceutical Inc.July 2025 Action & Verified Chart Pattern Trade Signals - sundaytimes.kr
Ultragenyx Investors Investigated for Securities Fraud and Unlawful Practices. - AInvest
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - FinancialContent
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Q2 2025 Earnings Call Transcript - MSN
Ultragenyx Says CRL Discussions ‘Productive’ Despite US FDA Leadership Upheaval - insights.citeline.com
Mereo BioPharma Group (MREO) Announced Progress in the Phase 3 Orbit Study Testing UX143 - Insider Monkey
Sarepta’s Woes Put the Stalwart AAV Under a Harsh Light - BioSpace
Cantor Fitzgerald Cuts Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $105.00 - MarketBeat
Reversal indicators forming on Ultragenyx Pharmaceutical Inc. stockWeekly Growth Portfolio Performance Summary - Newser
Technical Charts Suggest Momentum Shift in Ultragenyx Pharmaceutical Inc.Potential Breakout Stock List Published This Week - beatles.ru
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y - MSN
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityFree Triple Digit Return Stock Predictions - Newser
Signal strength of Ultragenyx Pharmaceutical Inc. stock in tech scannersHigh Conviction Stock Long-Term Summary - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionFree Weekly Setup With 3x Return Potential - Newser
Ultragenyx's Q2 earnings exceed expectations, price target lowered to $128 by Canaccord. - AInvest
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Just Reported Second-Quarter Earnings: Have Analysts Changed Their Mind On The Stock? - Yahoo Finance
Ultragenyx Pharmaceutical Analyst Ratings: Recent Assessments and Insights - AInvest
What makes Ultragenyx Pharmaceutical Inc. stock price move sharplyEquity Portfolio Outlook and Performance Summary - Newser
RBC Capital Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
FDA requests manufacturing changes for UX111 gene therapy - Sanfilippo Syndrome News
Ultragenyx Bets On Growth With Bullish Analyst Backing - Finimize
Ultragenyx Pharmaceutical Q2 2025 Earnings: Revenue Beats Expectations, Loss Narrows - AInvest
Ultragenyx Pharmaceutical Second Quarter 2025 Earnings: Beats Expectations - ca.finance.yahoo.com
‘Urgent need’ for treatment drives GTX-102 study enrollment - Angelman Syndrome News
Ultragenyx Pharmaceutical Inc. stock momentum explainedFree Proven Entry Plan With Low Risk Trade - Newser
Ultragenyx Earnings Call: Clinical Wins Amid Financial Challenges - TipRanks
‘On track to become profitable’: Marin County rare disorder drug maker narrows loss in Q2 - The North Bay Business Journal
Aspire Biopharma Holdings, Inc. shares rise 4.06% after-hours following Ultragenyx Pharmaceutical Inc. Q2 2025 earnings call. - AInvest
S&E In Brief: Launch Trends And Regulatory Updates Among SMID Biopharmas - insights.citeline.com
Ultragenyx Pharmaceutical: Strong Q2 Results and Promising Future Justify Buy Rating - TipRanks
Ultragenyx (RARE) Q2 Revenue Up 13% - Nasdaq
Ultragenyx Pharmaceutical Inc. SEC 10-Q Report - TradingView
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript - MarketBeat
Ultragenyx outlines $640M–$670M 2025 revenue target as clinical milestones advance - MSN
Ultragenyx: Q2 Earnings Snapshot - New Haven Register
Price action breakdown for Ultragenyx Pharmaceutical Inc.Long Term Equity Screener with Safety Metrics - Newser
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... - Yahoo Finance
Ultragenyx Pharmaceutical Q2 2025 Earnings Call Transcript: Financial Results and Business Update - AInvest
Ultragenyx Pharmaceutical Inc (RARE) Q2 2025 Earnings Call Highlights: Strong Revenue Growth ... By GuruFocus - Investing.com Canada
Ultragenyx Pharmaceuticals: A High-Stakes Play in Rare Disease Gene Therapy - AInvest
Ultragenyx's Q2 2025 Earnings Call: Dissecting Contradictions on Setrusumab Efficacy, FDA Interactions, and Resubmission Strategy - AInvest
Ultragenyx Sets 2025 Revenue Target at $640M-$670M Amid Clinical Advancements - AInvest
Ultragenyx Reports Growth Amidst Strategic Advancements - TipRanks
Earnings call transcript: Ultragenyx Q2 2025 beats EPS forecast, stock rises - Investing.com
Transcript : Ultragenyx Pharmaceutical Inc., Q2 2025 Earnings Call, Aug 05, 2025 - MarketScreener
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Ultragenyx Reports Better-Than-Expected Q2 Loss and RevenueNews and Statistics - IndexBox
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Ultragenyx Pharmaceutical Inc (RARE) 財務データ
収益
当期純利益
現金流量
EPS
0.41%
0.88%
大文字化:
|
ボリューム (24 時間):